-
Je něco špatně v tomto záznamu ?
Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q)
M. Belickova, J. Cermak, M. Dostalova Merkerova, J. Vesela, Z. Krejcik, E. Cechova, Z. Zemanova, K. Michalova, H. Votavova, M. Caniga, R. Neuwirtova, A. Jonasova,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS9634
MZ0
CEP - Centrální evidence projektů
- MeSH
- chromozomální delece * MeSH
- exprese genu účinky léků MeSH
- interleukin-1beta genetika metabolismus MeSH
- komplex proteinů 2-3 souvisejících s aktinem genetika metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidské chromozomy, pár 5 * MeSH
- lipopolysacharidové receptory krev genetika metabolismus MeSH
- monocyty účinky léků metabolismus MeSH
- myelodysplastické syndromy farmakoterapie genetika metabolismus MeSH
- nika kmenových buněk účinky léků genetika MeSH
- prognóza MeSH
- protoonkogenní proteiny c-jun genetika metabolismus MeSH
- senioři MeSH
- signální transdukce účinky léků genetika MeSH
- studie případů a kontrol MeSH
- thalidomid analogy a deriváty terapeutické užití MeSH
- TNF-alfa genetika metabolismus MeSH
- transkriptom účinky léků MeSH
- upregulace účinky léků genetika MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
UNLABELLED: We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14(+) monocytes from 6 patients with del(5q). Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway. BACKGROUND: Lenalidomide is an effective treatment for patients with del(5q) and myelodysplastic syndrome (MDS) The exact mechanism of lenalidomide function and its impact on the prognosis of patients is not known exactly. MATERIALS AND METHODS: We used gene expression profiling to study the effect of lenalidomide therapy in peripheral blood CD14(+) monocytes of 6 patients with del(5q) and MDS. RESULTS: After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level. This change in gene expression, in conjunction with increased expression of repressed genes that affect the stem cell niche (ie, CXCR4 and CRTAP), may exert a positive effect on treated patients. In contrast, we found that increased expression of the ARPC1B gene may have a negative impact on the stability of patient remission. CONCLUSION: The observed changes in gene expression described here may contribute to the identification of pathways that are affected by lenalidomide, which may help to explain the effects of this drug.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024430
- 003
- CZ-PrNML
- 005
- 20170110112125.0
- 007
- ta
- 008
- 130703s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clml.2012.04.003 $2 doi
- 035 __
- $a (PubMed)22608605
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Belickova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. monika.belickova@uhkt.cz
- 245 10
- $a Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q) / $c M. Belickova, J. Cermak, M. Dostalova Merkerova, J. Vesela, Z. Krejcik, E. Cechova, Z. Zemanova, K. Michalova, H. Votavova, M. Caniga, R. Neuwirtova, A. Jonasova,
- 520 9_
- $a UNLABELLED: We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14(+) monocytes from 6 patients with del(5q). Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway. BACKGROUND: Lenalidomide is an effective treatment for patients with del(5q) and myelodysplastic syndrome (MDS) The exact mechanism of lenalidomide function and its impact on the prognosis of patients is not known exactly. MATERIALS AND METHODS: We used gene expression profiling to study the effect of lenalidomide therapy in peripheral blood CD14(+) monocytes of 6 patients with del(5q) and MDS. RESULTS: After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level. This change in gene expression, in conjunction with increased expression of repressed genes that affect the stem cell niche (ie, CXCR4 and CRTAP), may exert a positive effect on treated patients. In contrast, we found that increased expression of the ARPC1B gene may have a negative impact on the stability of patient remission. CONCLUSION: The observed changes in gene expression described here may contribute to the identification of pathways that are affected by lenalidomide, which may help to explain the effects of this drug.
- 650 _2
- $a komplex proteinů 2-3 souvisejících s aktinem $x genetika $x metabolismus $7 D051376
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lipopolysacharidové receptory $x krev $x genetika $x metabolismus $7 D018950
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 12
- $a chromozomální delece $7 D002872
- 650 12
- $a lidské chromozomy, pár 5 $7 D002895
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a exprese genu $x účinky léků $7 D015870
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukin-1beta $x genetika $x metabolismus $7 D053583
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a monocyty $x účinky léků $x metabolismus $7 D009000
- 650 _2
- $a myelodysplastické syndromy $x farmakoterapie $x genetika $x metabolismus $7 D009190
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a protoonkogenní proteiny c-jun $x genetika $x metabolismus $7 D016755
- 650 _2
- $a signální transdukce $x účinky léků $x genetika $7 D015398
- 650 _2
- $a nika kmenových buněk $x účinky léků $x genetika $7 D055153
- 650 _2
- $a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792
- 650 _2
- $a transkriptom $x účinky léků $7 D059467
- 650 _2
- $a TNF-alfa $x genetika $x metabolismus $7 D014409
- 650 _2
- $a upregulace $x účinky léků $x genetika $7 D015854
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cermak, Jaroslav $u -
- 700 1_
- $a Dostalova Merkerova, Michaela $u -
- 700 1_
- $a Veselá, Jitka $u - $7 xx0209625
- 700 1_
- $a Krejcik, Zdenek $u -
- 700 1_
- $a Cechova, Eliska $u -
- 700 1_
- $a Zemanova, Zuzana $u -
- 700 1_
- $a Michalova, Kyra $u -
- 700 1_
- $a Votavova, Hana $u -
- 700 1_
- $a Caniga, Miroslav $u -
- 700 1_
- $a Neuwirtova, Radana $u -
- 700 1_
- $a Jonasova, Anna $u -
- 773 0_
- $w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 12, č. 5 (2012), s. 375-383
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22608605 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20170110112222 $b ABA008
- 999 __
- $a ok $b bmc $g 988110 $s 822810
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 12 $c 5 $d 375-383 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
- GRA __
- $a NS9634 $p MZ0
- LZP __
- $a Pubmed-20130703